AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Tango Therapeutics: Third Rock Ventures IV Sells 302,194 Shares at $7/Share
ByAinvest
Tuesday, Aug 26, 2025 7:09 pm ET1min read
Tango Therapeutics, Inc. (TNGX) has announced that 10% Owner Third Rock Ventures IV, L.P. has disposed of 302,194 shares at a price of $7 per share on August 22, 2025.
Tango Therapeutics, Inc. (TNGX), a clinical-stage biotechnology company, has reported that its 10% owner, Third Rock Ventures IV, L.P., has disposed of 302,194 shares of the company's common stock. The transaction occurred on August 22, 2025, at an average price of $7 per share [1].The disposal of these shares was reported in a recent SEC Form 4 filing submitted by Third Rock Ventures IV, L.P. The filing details the transaction and provides information about the beneficial ownership of the shares. According to the filing, the shares were sold in multiple transactions at prices ranging from $7.00 to $7.05, inclusive [1].
Third Rock Ventures IV, L.P. is a venture capital firm that has invested in various biotechnology and pharmaceutical companies. The firm's investment in Tango Therapeutics, Inc. is significant, with the firm holding a 10% stake in the company. The disposal of shares by the firm is likely a strategic move to manage its investment portfolio and liquidate some of its holdings.
The disposal of these shares by Third Rock Ventures IV, L.P. may have implications for the stock price of Tango Therapeutics, Inc. (TNGX). The market may react to the news of the share disposal, especially if it is seen as a sign of the firm's confidence in the company's future prospects. However, it is important to note that the disposal of shares by a single investor, even one as significant as Third Rock Ventures IV, L.P., may not have a substantial impact on the overall market sentiment towards the company.
Investors and financial professionals should closely monitor the news and market reactions to the share disposal by Third Rock Ventures IV, L.P. to assess its potential impact on Tango Therapeutics, Inc. (TNGX) and the broader biotechnology sector.
References:
[1] https://www.stocktitan.net/sec-filings/TNGX/form-4-tango-therapeutics-inc-insider-trading-activity-b301b42a2a30.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet